Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 12Recruiting 10Active not recruiting 10Terminated 9Unknown 4Withdrawn 3

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1

Conditions

Melanoma 4Neoplasms 1Neoplasm Metastasis 1

Interventions

Nivolumab 25pembrolizumab 21Ipilimumab 15Temozolomide 13toripalimab 12Biopsy 10Imiquimod 8Cyclophosphamide 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4fludarabine 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Injections 4Bevacizumab 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × binimetinib × Dermatologic × Clear all
NCT04720768 2024-01-05

CELEBRATE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
78 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT05767879 2023-03-14

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Leiden University Medical Center

Phase 2 Unknown
28 enrolled
Dermatologic

Melanoma

NCT05103891 2021-12-01

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Pierre Fabre Medicament

Phase 1 Unknown
14 enrolled
Dermatologic

Melanoma

NCT05097378 2021-10-28

PREMIUM

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown
45 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡